

# TENTATIVE PROGRAM



ECNP2021

| Monday, 31 May 2021   |   |
|---|---|
| 09:00 Exhibit Hall Opens  |   |
| 12:00-13:00 Visit the Exhibition Hall and ePosters (Quick Pitch Sessions in round table rooms)                      |   |
| 13:00 -13:15 Welcome by the Congress President – Bjarne Winther Kristensen, Copenhagen, Denmark                     |   |
| <b>13:15-14:00 - Plenary Lecture 1</b>  |   |
| 13:15   | Chair: Bjarne Winther Kristensen, Copenhagen, Denmark (3 min)<br><b>Brain tumor diagnosis in transition - from single parameter analyses to multiomics (30+12)</b><br>Andreas von Deimling, Heidelberg, Germany |
| <b>14:00-15:30 – Symposium 1: Cerebrovascular diseases</b>  |   |
|   | <b>Chairs:</b> Raj Kalara, Newcastle, UK and Kate Lykke Lambertsen, Odense, Denmark (5 min)   |
| 14:05   | <b>S1.1 Post-stroke inflammation – target or tool for therapy (18+5)</b><br>Kate Lykke Lambertsen, Odense, Denmark  |
| 14:28   | <b>S1.2 White matter in familial small vessel diseases: CADASIL (18+5)</b><br>Anne Joutel, Paris, France  |
| 14:51   | <b>S1.3 White matter disease – small vessel pathology and more (18+5)</b><br>Elisabet Englund, Lund, Sweden   |
| 15:13   | <b>S1.4 (P207) Regional proteomic mapping of the human vanishing white matter brain (5+3)</b><br>Jodie Man, Utrecht, the Netherlands  |
| 15:22   | <b>S1.5 (P210) Volume and cell number of the hippocampus in depression, schizophrenia, and suicide subjects (5+3)</b><br>Karl-Anton Dorph-Petersen, Aarhus, Denmark   |
| <b>14:00-15:30 – Symposium 2: Genetics of neurodegeneration</b>   |   |
|   | Chairs: Irina Alafuzoff, Uppsala, Sweden, and Colin Smith, Edinburgh, Scotland  |
| 14:05   | <b>S2.1 Clues to the aetiology of neurodegenerative diseases from genomic analysis (18+5)</b><br>John Hardy, London, UK   |
| 14:28   | <b>S2.2 Pathology of genetic and sporadic Parkinson's disease (18+5)</b><br>Steve Gentleman, London, UK   |
| 14:51   | <b>S2.3 Genetics of MND/ALS - from genes to translational approaches (18+5)</b><br>Pam Shaw, Sheffield, UK  |
| 15:14   | Panel Discussion (15 )  |
| <b>14:00-15:30 – Symposium 3. CNS tumor precision oncology – what is important in the neuropathological setting</b> |   |
|   | <b>Chairs:</b> Werner Paulus, Münster, Germany and Christine Haberler, Vienna, Austria (5 min)  |
| 14:05   | <b>S3.1 The laboratory setup needed for CNS tumor precision oncology (15+5)</b><br>Felix Sahm, Heidelberg, Germany  |
| 14:25   | <b>S3.2. Experience and results from a precision oncology phase I unit (15+5)</b><br>Ulrik Lassen, Copenhagen, Denmark  |
| 14:45   | <b>S3.3 Molecular diagnostics of brain tumors - current practice and the next frontiers (15+5)</b><br>Sebastian Brandner, London, United Kingdom  |
| 15:05   | <b>S3.4 (P129) Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma (5+3)</b><br>Christian Mirian, Copenhagen/Geneva, Denmark/Switzerland                                     |

|  |   |  |
|--|---|--|
| 15:13  | <b>S3.5 (P123) Diffuse midline glioma, H3 K27M-mutant (DMG,H3) with BRAF V600E mutation. Presentation of two cases treated with BRAF V600 inhibitors (5+3)</b><br>Mónica Mezmezian, Buenos Aires, Argentina |  |
| 15:21  | <b>S3.6 (P194) Nanocarrier using protoporphyrin IX-loaded albumin nanoemulsion for image-guided glioblastoma therapies (5+3)</b><br>Luciano Neder, Ribeirao Preto, Brazil                                   |  |
| <b>15:30-15:45 – BREAK.</b> Please visit the Exhibition Hall and ePosters                    |   |  |
| <b>15:45-17:15 - Workshop 1. Primary Tauopathies</b>   |   |  |
|  | Chairs: Gabor Kovacs, Toronto, Canada and Dennis Dickson, Jacksonville, Florida, USA  |  |
| 15:50  | <b>W1.1 Overview of tau pathologies: Interactive slide session using scanned slides (20+5)</b><br>Gabor Kovacs, Toronto, Canada   |  |
| 16:15  | <b>W1.2 Tau pathology related to brain trauma (20+5)</b><br>Colin Smith, Edinburgh, Scotland  |  |
| 16:40  | <b>W1.3 (P023) Deconvolving the individual contributions of comorbid tau neuropathologies using deep learning (5+3)</b><br>Anthony Vega, Dallas, Texas, USA   |  |
| 16:488   | <b>W1.4 (P019) Aggregates of RNA binding proteins and ER chaperones linked to exosomes in granulovacuolar degeneration of the Alzheimer's disease brain (5+3)</b><br>Alfred Yamoah, Aachen, Germany         |  |
| 16:56  | <b>W1.5 (P018) Tau related changes in post mortem retina in Alzheimer's disease and other tauopathies (5+3)</b><br>Jeroen Hoozemans, Amsterdam, the Netherlands   |  |
| 17:04  | <b>Panel Discussion (11)</b>  |  |
| <b>15:45-17:15 Workshop 2. Muscle biopsy and molecular biology: a successful cooperation</b> |   |  |
|  | Chairs: Lammens, Antwerpen, Belgium and Werner Stenzel, Berlin, Germany (4 min)   |  |
| 15:49  | <b>W2.1 Interactive case discussions (8+5)</b><br>Eleonora Aronica, Amsterdam, the Netherlands  |  |
| 16:02  | <b>W2.2 Interactive case discussions (8+5)</b><br>Joachim Weis, Aachen, Germany   |  |
| 16:15  | <b>W2.3 Interactive case discussions (8+5)</b><br>Willem de Ridder, Antwerp, Belgium  |  |
| 16:28  | <b>W2.4 Interactive case discussions (8+5)</b><br>Eleonora Aronica, Amsterdam, the Netherlands  |  |
| 16:41  | <b>W2.5 Interactive case discussions (8+5)</b><br>Wilfred den Dunnen, Groningen, the Netherlands  |  |
| 16:54  | <b>W2.6 Interactive case discussions (8+5)</b><br>Werner Stenzel, Berlin, Germany   |  |
| 17:07  | <b>W2.7 (P206) Automated large-scale scanning transmission electron microscopy of myopathies with structural abnormalities (5+3)</b><br>Carsten Dittmayer, Berlin, Germany                                  |  |
| <b>15:45-17:15 – Workshop 3. Pituitary and sellar lesions</b>                                |   |  |
|  | Chairs: Olivera Casar-Borota, Uppsala, Sweden and Henning Boldt, Odense, Denmark (5 min)  |  |
| 15:50  | <b>W3.1 The 2017 WHO classification of pituitary neuroendocrine neoplasms. What have we learnt? (14+3)</b><br>Olivera Casar-Borota, Uppsala, Sweden   |  |
| 16:07  | <b>W3.2 Morphology meets genomics and epigenomics: should we move towards an integrated tissue diagnosis of PitNETs (14+3)</b><br>Olaf Ansorge, Oxford, UK  |  |
| 16:24  | <b>W3.3 Molecular pathways and targets in pituitary tumors (14+3)</b><br>Marily Theodoropoulou, Munich, Germany   |  |
| 16:41  | <b>W3.4 Pituitary lesions from an endocrinologist's perspective (14+3)</b>  |  |

|  |  |  |
|--|--|--|
|  | Marianne Andersen, Odense, Denmark   |  |
| 16:58  | <b>W3.5 Interactive slide-based case presentations (14+3)</b><br>Olaf Ansorge, Oxford, UK  |  |
| <b>17:15-17:30 – BREAK.</b> Please visit the Exhibition Hall and ePosters                        |  |  |
| <b>17:30-18:15 - Plenary Lecture 2</b>   |  |  |
| 17:30-18:15  | Chair: Paul Ince, Sheffield, UK (3 min)<br><b>Lessons learned from brain banking for neurodegenerative diseases (30+12)</b><br>Dennis Dickson, Jacksonville, FL, USA<br>(Lecture supported by BNS and NAN) |  |
| <b>Tuesday, 1 June 2021</b>  |  |  |
| 12:00-13:00 - Visit the Exhibition Hall and ePosters (Quick Pitch Sessions in round table rooms) |  |  |
| <b>13:00-13:45 – Plenary Lecture 3</b>   |  |  |
|  | Chair: Eleonora Aronica, Amsterdam, the Netherlands (3 min)<br><b>Brain somatic mutations in focal cortical dysplasias (30+12)</b><br>Stéphanie Baulac, Paris, France                                      |  |
| <b>13:45-14:00 Break.</b> Please visit the Exhibition Hall and ePosters                          |  |  |
| <b>14:00-15:30 - Symposium 4. The 2021 WHO CNS tumor classification: The Fifth!</b>              |  |  |
|  | Chairs: Pieter Wesseling, Amsterdam/Utrecht, the Netherlands and Guido Reifenberger, Düsseldorf, Germany   |  |
| 14:05  | <b>S4.1 From cIMPACT-NOW to WHO 2021 classification of CNS tumors (16+4)</b><br>Pieter Wesseling, Amsterdam/Utrecht, the Netherlands   |  |
| 14:25  | <b>S4.2 The WHO 2021 classification of diffuse gliomas (adult &amp; pediatric) (16+4)</b><br>Guido Reifenberger, Düsseldorf, Germany   |  |
| 14:45  | <b>S4.3 The WHO 2021 classification of circumscribed gliomas and glioneuronal tumors (16+4)</b><br>Dominique Figarella-Branger, Marseille, France  |  |
| 15:05  | <b>S4.4 (25)</b><br>Panel Discussion   |  |
| <b>14:00-15:30 -Symposium 5. Mechanisms of brain Inflammation</b>                                |  |  |
|  | Chairs: Hans Lassmann, Vienna, Austria, and Trevor Owens, Odense, Denmark  |  |
| 14:05  | <b>S5.1 Pathways of drainage of interstitial and cerebrospinal fluids from the brain. Significance for neurological diseases (20+3)</b><br>Roxana Carare, Southampton, UK                                  |  |
| 14:28  | <b>S5.2 Immune cell interaction with the blood-brain barrier in the pathogenesis of inflammation (20+3)</b><br>Britta Engelhardt, Bern, Switzerland  |  |
| 14:51  | <b>S5.3 Pathology of different human inflammatory CNS diseases – an expanding spectrum (20+3)</b><br>Hans Lassmann, Vienna, Austria  |  |
| 15:14  | <b>S5.4 Panel discussion (15 min)</b>  |  |
| <b>14:00-15:30 – Symposium 6. Immuno-oncology</b>  |  |  |
| 14:00  | Chairs: Anna Berghof, Vienna, Austria and Bjarne Kristensen, Odense, Denmark   |  |
| 14:05  | <b>S6.1 The inflammatory microenvironment as a therapeutic target in glioma (16+4)</b><br>Anna Berghof, Vienna, Austria  |  |
| 14:25  | <b>S6.2 Genetic changes and T-cell infiltration in gliomas (16+4)</b><br>Pim French, Amsterdam, the Netherlands  |  |
| 14:45  | <b>S6.3 Understanding and targeting the microenvironment in IDH-mutant gliomas (16+4)</b><br>Lukas Bunse, Mannheim, Germany  |  |
| 15:05  | <b>S6.4 (P111) Single-cell analysis of tumor-associated microglia and macrophages from human glioblastoma (5+3)</b>  |  |

|   |  |  |
|---|--|--|
|   | Rikke Sick Andersen, Odense, Denmark   |  |
| 15:13   | <b>S6.5 (P115) Deconvolution of immunotherapy-treated glioblastoma identifies cellular heterogeneity and plasticity at the single-cell level (5+3)</b><br>Josephine Deleuran Hendriksen, Copenhagen, Denmark |  |
| 15:21   | <b>S6.6 (P135) Defects of mismatch repair proteins in pediatric high grade gliomas (5+3)</b><br>Christine Haberler, Vienna, Austria  |  |
| <b>15:30-15:45 – BREAK.</b> Please visit the Exhibition Hall and ePosters   |  |  |
| <b>15:45-17:15 – Workshop 4. Slide seminar on human prion diseases: histotyping and identification of atypical phenotypes</b> |  |  |
| 15:45   | Chairs: Ellen Gelpi, Vienna, Austria, and Piero Parchi, Bologna, Italy   |  |
| 15:50   | <b>W4.1 Interactive histotyping of CJD subtypes including genetic and atypical forms (85 minutes total)</b><br>Ellen Gelpi and Piero Parchi Gelpi and Parchi   |  |
| <b>15:45-17:15 – Workshop 5. Case discussions of CNS tumors with multi-layered information</b>                                |  |  |
| 15:45   | Chairs: Felix Sahm, Heidelberg, Germany, and David Capper, Berlin, Germany   |  |
| 15:50   | <b>W5.1. Practical NGS evaluation (20+8)</b><br>Felix Sahm, Heidelberg, Germany  |  |
| 16:18   | <b>W5.2. Practical DNA methylation evaluation (20+8)</b><br>David Capper, Berlin, Germany  |  |
| 16:46   | <b>W5.3. Interactive case discussions (28)</b><br>Felix & David Sahm & Capper  |  |
| <b>15:45-17:15 – Workshop 6. Developmental neuropathology: recent advances and future challenges</b>                          |  |  |
| 15:45   | Chairs: Eleonora Aronica, Amsterdam, the Netherlands, and Karen Bonde Larsen, Copenhagen, Denmark  |  |
| 15:50   | <b>W6.1 The value of postmortem examination in neurodevelopmental diseases (15+5)</b><br>Homa Adle-Biasette, Paris, France   |  |
| 16:10   | <b>W6.2. Interneurons in cerebral cortical developmental disorders (15+5)</b><br>Jeffrey Golden, Boston, USA   |  |
| 16:30   | <b>W6.3 Neuropathology of focal cortical dysplasias: 2021 update (15+5)</b><br>Ingmar Blümcke, Erlangen, Germany   |  |
| 16:50   | <b>W6.4 Panel Discussion (25)</b>  |  |
| <b>17:15-17:30 – BREAK.</b> Please visit the Exhibition Hall and ePosters   |  |  |
| <b>17:30-18:30 FREE COMMUNICATIONS I-II-III</b>   |  |  |
| <b>Wednesday, 2 June 2021</b>   |  |  |
| 12:00-13:00 - Visit the Exhibition Hall and ePosters (Quick Pitch Sessions in round table rooms)                              |  |  |
| <b>13:00-13:45 – Plenary Lecture 4</b>  |  |  |
| 13:00   | Chair: David Scheie, Copenhagen, Denmark (3 min)<br><b>The invasive behavior of glioma cells in the CNS and their biological characteristics (30+12)</b><br>Rolf Bjerkvig, Bergen, Norway                    |  |
| <b>13:45-14:00 - Break.</b> Please visit the Exhibition Hall and ePosters   |  |  |
| <b>14:00-15:30 - Symposium 7. TDP-43 proteinopathies</b>  |  |  |
| 14:00   | Chairs: Manuela Neumann, Tübingen, Germany, and Olaf Ansorge, Oxford, UK (5)   |  |
| 14:05   | <b>S7.1 Neuropathology of FTLD-TDP (25+5)</b><br>Ian Mackenzie, Vancouver, Canada  |  |
| 14:35   | <b>S7.2 Cellular and system vulnerability in ALS (25+5)</b><br>Olaf Ansorge, Oxford, UK  |  |

|  |  |  |
|--|--|--|
| 15:05  | <b>S7.3 (P009) Cognitive decline in amyotrophic lateral sclerosis: neuropathological substrate and genetic determinants (5+3)</b><br>Sergi Borrego-Écija, Barcelona, Spain                                       |  |
| 15:13  | <b>S7.4 (P011) Neuroanatomy of FTD: whole-brain correlations between symptoms and pathologies (5+3)</b><br>Marta Scarioni, Amsterdam, the Netherlands  |  |
| 15:21  | <b>S7.5 (P033) Defining and diagnosing neurodegenerative movement disorders through integrated analysis of genetics and neuropathology (MD-GAP) (5+3)</b><br>Lesley Wu, London, UK                               |  |
| <b>14:00-15:30 – Symposium 8. Myositis – clinical, morphological and differential diagnostic highlights</b>                            |  |  |
| 14:00  | Chairs: Werner Stenzel, Berlin, Germany, and Anne Schänzer, Giessen, Germany   |  |
| 14:05  | <b>S8.1 Clinical diagnostic aspects in myositis (18+5)</b><br>Olivier Benveniste, Parijs, France   |  |
| 14:28  | <b>S8.2 Morphological diagnostic aspects in myositis (18+5)</b><br>Werner Stenzel, Berlin, Germany   |  |
| 14:51  | <b>S8.3 Differential diagnostic aspects in myositis (18+5)</b><br>Benedikt Schoser, München, Germany   |  |
| 15:14  | <b>S8.4 (P205) Differential diagnosis of vacuolar myopathies in the NGS era (5+3)</b><br>Joachim Weis, Aachen, Germany   |  |
| 15:22  | <b>S8.5 (P199) NanoString technology distinguishes anti-TIF-1<math>\gamma</math>+ from anti-Mi-2+ dermatomyositis patients (5+3)</b><br>Josephine Radke, Berlin, Germany   |  |
| <b>14:00-15:30 – Symposium 9. White matter and oligodendrocyte pathology: new insights in neurodevelopmental diseases and epilepsy</b> |  |  |
| 14:00  | Chairs: Eleonora Aronica, Amsterdam, the Netherlands, and Karen Bonde Larsen, Copenhagen, Denmark (5 min)  |  |
| 14:05  | <b>S9.1 White matter pathology in vanishing white matter: the role of astroglial pathology (16+4)</b><br>Marianna Bugiani, Amsterdam, the Netherlands  |  |
| 14:25  | <b>S9.2 Myelin loss and oligodendrocyte pathology in tuberous sclerosis and other mTORopathies (16+4)</b><br>Angelika Muehleberner, Amsterdam, the Netherlands   |  |
| 14:45  | <b>S9.3 White matter in temporal lobe epilepsy: clinico-pathological correlates (16+4)</b><br>Maria Thom, London, UK   |  |
| 15:05  | <b>S9.4 (P081) Mimicking white matter pathology in a 3D-nanofiber cell culture system derived from children with drug-resistant epilepsies (5+3)</b><br>Victoria-Elisabeth Gruber, Vienna, Austria               |  |
| 15:13  | <b>S9.5 (P082) DNA methylation-based classification of malformations of cortical development (5+3)</b><br>Ingmar Bluemcke, Erlangen, Germany   |  |
| 15:21  | <b>S9.6 (P080) The antiseizure and antiepileptogenic effect of matrix metalloproteinase inhibitor IPR-179 and its potential mechanisms of action (5+3)</b><br>Diede W. Broekaart, Amsterdam, the Netherlands     |  |
| <b>15:30-15:45 - Break. Please visit the Exhibition Hall and ePosters</b>  |  |  |
| <b>15:45-17:15 - Workshop 7. Assessment of the contributions of mixed pathologies in the ageing brain</b>                              |  |  |
| 15:45  | Chairs: Colin Smith, Edinburgh, Scotland, and Irina Alafuzoff, Uppsala, Sweden   |  |
| 15:50  | <b>W7.1 Mixed pathology in the aged demented (15+3)</b><br>Johannes Attems, Newcastle, UK  |  |
| 16:08  | <b>W7.2 Amygdala, a hotspot of pathology in aged (15+3)</b><br>Irina Alafuzoff, Uppsala, Sweden  |  |
| 16:26  | <b>W7.7 Interactive slide session using scanned slides (15)</b><br>t.b.d.  |  |
| 16:41  | <b>W7.3 (P037) Unique changes in gene activity in the ventral midbrain precedes dopaminergic degeneration in Parkinson's disease mouse models (5+3)</b><br>Pierre Garcia, Dudelange/Esch-sur-Alzette, Luxembourg |  |

|   |  |  |
|---|--|--|
| 16:49   | <b>W7.4 (P021) Subregional severity of proteinopathies in the hippocampus of late onset Alzheimer's Disease (AD) and Dementia with Lewy Bodies (DLB) patients (5+3)</b><br>Sonja Fixemer, Dudelange/ Belval, Luxembourg          |  |
| 16:57   | <b>W7.5 (P026) Limbic-predominant age-related TDP-43 encephalopathy (LATE) in a cohort of patients with dementia: evidence of an early phase of hippocampal sclerosis (5+3)</b><br>Alicia Uceda Heras, Madrid, Spain             |  |
| 17:05   | <b>W7.6 (P022) Diabetes is associated with vascular dementia, not Alzheimer's disease or Lewy body dementia (5+3)</b><br>Keivan Javanshiri, Lund, Sweden   |  |
| <b>15:45-17:15 – Workshop 8. Progress in the pathological diagnosis of pediatric and adult CNS tumors</b> |  |  |
| 15:45   | Chairs: Pietsch, Bonn, Germany, and Dominique Figarella-Branger, Marseille, France   |  |
| 15:50   | <b>W8.1. Molecular pathology of epilepsy-related low-grade lesions (15+5)</b><br>Tom Jacques, London, UK   |  |
| 16:10   | <b>W8.2 Modern diagnostics of ependymal tumors (15+5)</b><br>Dominique Figarella-Branger, Marseille, France  |  |
| 16:30   | <b>W8.3 Differential diagnostics of primitive "embryonal" tumors (15+5)</b><br>Torsten Pietsch, Bonn, Germany  |  |
| 16:50   | <b>8.4. (P118) EpiDiP.org: an open access epigenomics diagnostic resource (5+3)</b><br>Juergen Hench, Basel, Switzerland   |  |
| 16:58   | <b>W8.5 (P102) Establishment of Droplet Digital™ PCR (ddPCR™) for rapid molecular diagnostics of brain tumors (5+3)</b><br>Guido Reifenberger, Düsseldorf/Heidelberg, Germany  |  |
| 17:06   | <b>W8.6 (P127) Identification of two main subgroups among posterior pituitary tumors associated with histology, MAPK/PI3K mutations, epigenetic regulator mutations, CNV and outcome (5+3)</b><br>Simone Schmid, Berlin, Germany |  |
| <b>15:45-17:15 – Workshop 9. B cells in inflammatory demyelinating diseases</b>                           |  |  |
| 15:45   | Chairs: Hans Lassmann, Vienna, Austria, and Trevor Owens, Odense, Denmark  |  |
| 15:50   | <b>W9.1 B-cell inflammation in MS (14+3)</b><br>Marvin van Luijn, Rotterdam, the Netherlands   |  |
| 16:07   | <b>W9.2 Roles of B-cells in MS and potential consequences for therapy (14+3)</b><br>Amit Bar-Or, Philadelphia, USA   |  |
| 16:24   | <b>W9.3 Antibody mediated autoimmune diseases of the nervous system (14+3)</b><br>Romana Höftberger, Vienna, Austria   |  |
| 16:41   | <b>W9.4 MOG encephalomyelitis and NMOs – insights from animal models (14+3)</b><br>Trevor Owens, Odense, Denmark   |  |
| 16:58   | <b>W9.5 The CD20+ T cell: a wolf in sheep's clothing? (14+3)</b><br>Marina von Essen, Copenhagen, Denmark  |  |
| <b>17:15-17:30 – BREAK.</b> Please visit the Exhibition Hall and ePosters                                 |  |  |
| <b>17:30-18:30 - FREE COMMUNICATIONS IV-V-VI</b>  |  |  |
| <b>Thursday, 3 June</b>   |  |  |
| 11:30-13:00 ISN Business Meeting (For ISN Council & Executive Committee only (upon invitation))           |  |  |
| 12:00-13:00 - Visit the Exhibition Hall and ePosters (Quick Pitch Sessions in round table rooms)          |  |  |
| <b>13:00-13:45 Plenary Lecture 5</b>  |  |  |
|   | Chair: Joachim Weis, Aachen, Germany (3 min)<br><b>Polyglucosan storage in muscle and brain - disease entities and pathogenesis (30+12)</b><br>Berge Minassian, Dallas, USA  |  |
| 13:45-14:00 BREAK. Please visit the Exhibition Hall and ePosters  |  |  |
| <b>14:00-15:30 Symposium 10. Neuropathology training, Courses and Examination (EFN) in Europe</b>         |  |  |

|   |  |  |
|---|--|--|
| 14:00   | Chairs: Tibor Hortobagyi, Debrecen/Szeged, Hungary and Wilfred den Dunnen, Groningen, the Netherlands  |  |
| 14:05   | <b>Round-table' discussion, with lecturers and participants of Euro-CNS courses, examiners and candidates of EFN examinations. Neuropathology training across Europe: the current situation and challenges of the future</b> |  |
| <b>14:00-15:30 - S11. Intratumoral heterogeneity</b>                      |  |  |
| 14:00   | Chairs: Rolf Bjerkvig, Bergen, Norway, and Hrvoje Miletic, Bergen, Norway  |  |
| 14:05   | <b>S11.1 Longitudinal molecular trajectories of diffuse glioma in adults (14+3)</b><br>Roel Verhaak, Bar Harbor, Maine, USA  |  |
| 14:22   | <b>S11.2 Epigenomic contribution to glioblastoma heterogeneity (14+3)</b><br>Adelheid Woehrer, Vienna, Austria   |  |
| 14:39   | <b>S11.3 Role of intrinsic tumor plasticity and microenvironment in creating intratumoral heterogeneity in glioblastoma (14+3)</b><br>Anna Golebiewska, Luxembourg, Luxembourg   |  |
| 14:56   | <b>S11.4 Brain tumor invasion into the CNS - mechanisms of action (14+3)</b><br>Rolf Bjerkvig, Bergen, Norway  |  |
| 15:13   | <b>S11.5 (P095) Subependymoma of the posterior fossa may progress to ependymoma: Role of TERT mutation, loss of chromosome 6 and methylome alterations (5+3)</b><br>Christian Thomas, Münster, Germany                       |  |
| 15:21   | <b>S11.6 (P128) Integrated analysis of molecular alterations and immune cell infiltration in primary and recurrent glioblastomas (5+3)</b><br>Jeanette Krogh Pedersen, Odense, Denmark                                       |  |
| <b>14:00-15:30 – Symposium 12. Dynamic aspects of amyloid-β</b>           |  |  |
|   | Chairs: James Nicoll, Southampton, UK, and Zane Jaunmuktane, London, UK  |  |
| 14:05   | <b>S12.1 The relationship between spreading and maturation of amyloid-b pathology in AD (15+5)</b><br>Dietmar Thal, Leuven, Belgium  |  |
| 14:25   | <b>S12.2 Evidence for the person to person transmissibility of amyloid-β. (15+5)</b><br>Zane Jaunmuktane, London, UK   |  |
| 14:45   | <b>S12.3 Removal of amyloid-β from the brain by immunotherapy (15+5)</b><br>James Nicoll, Southampton, UK  |  |
| 15:05   | <b>S12.4 (P017) Alzheimer's disease neuropathological change and loss of neuropil and matrix in idiopathic normal pressure hydrocephalus, a model of Alzheimer's disease (5+3)</b><br>Sylwia Libard, Uppsala, Sweden         |  |
| 15:13   | <b>S12.5 (P020) The coarse-grained plaque: a divergent Aβ plaque-type in early-onset Alzheimer's disease (5+3)</b><br>Baayla Boon, Amsterdam, the Netherlands  |  |
| 15:21   | <b>S12.6 (P024) Systemic infection exacerbates cerebral hypoperfusion and blood-brain-barrier breakdown in Alzheimer's disease and vascular dementia (5+3)</b><br>Daniel Asby, Bristol, UK                                   |  |
| <b>15:30 – 15:45 BREAK.</b> Please visit the Exhibition Hall and ePosters |  |  |
| <b>15:45-17:15 – Symposium 13. COVID-19 and neuropathology</b>            |  |  |
| 15:45   | Chairs: Safa Al-Sarraj, London, UK, and Markus Glatzel, Hamburg, Germany   |  |
| 15:50   | <b>S13.1 Brain pathology of COVID-19 (20+3)</b><br>Markus Glatzel, Hamburg, Germany  |  |
| 16:13   | <b>S13.2 COVID-19 encephalitis; the pathological evidence (20+3)</b><br>Safa Al-Sarraj, London, UK   |  |
| 16:36   | <b>S13.3 (P234) Olfactory transmuscoal SARS-CoV2- invasion as port of CNS entry in COVID-19 (7+3)</b><br>Jenny Meinhardt, Berlin, Germany  |  |
| 16:46   | <b>S13.4 (P231) Post infectious myopathy related to COVID-19 (7+3)</b><br>Leila Chimelli, Rio de Janeiro, Brazil   |  |
| 16:45   | <b>Panel discussion (19)</b>   |  |



|   |  |  |
|---|--|--|
|   |  |  |
| <b>17:15-17:30 – BREAK.</b> Please visit the Exhibition Hall and ePosters |  |  |
| <b>17:30-18:15 Plenary Lecture 6</b>                                      |  |  |
|   | Chair: Eva Løbner Lund, Copenhagen, Denmark (3 min)<br><b>Deciphering phenotypic variability and transmission properties of human prion diseases (30+12)</b><br>Piero Parchi, Bologna, Italy |  |
| <b>18:15-18:30 Prizes and Closure</b>                                     |  |  |